Development of a novel anti-canine CD20 monoclonal antibody with diagnostic and therapeutic potential

Daisuke Ito, Susan Brewer, Jaime F. Modiano, Melissa J. Beall

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

In humans, passive immunotherapy with anti-CD20 monoclonal antibodies (mAbs) has created immeasurable improvements in outcomes of patients with B-cell malignancies. However, the lack of comparable reagents has precluded development of this approach in dogs. We developed a novel anti-canine CD20 mAb designated as 6C8. 6C8 recognized the extracellular domain of canine CD20 and showed high-affinity binding to canine CD20 in solution, as well as in its native conformation on canine B-cells. The 6C8 target was expressed invariably in B-cell lineage cells, but not in T-cells or myeloid cells. 6C8 promoted phagocytosis of B-cell lymphoma cells by macrophages, but in its current framework, it did not induce direct cytotoxicity or complement dependent cytotoxicity. In summary, we have established a novel anti-canine CD20 mAb that is useful as a diagnostic tool to phenotype B-cells, and which could be integrated as a tool for passive immunotherapy to treat dogs with B-cell disorders.

Original languageEnglish (US)
Pages (from-to)219-225
Number of pages7
JournalLeukemia and Lymphoma
Volume56
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Canidae
B-Lymphocytes
Monoclonal Antibodies
Passive Immunization
Dogs
Therapeutics
B-Cell Lymphoma
Cell Lineage
Myeloid Cells
Phagocytosis
Macrophages
T-Lymphocytes
Phenotype
Neoplasms

Keywords

  • B-cell lymphoma
  • CD20
  • Dogs
  • Monoclonal antibody
  • Phagocytosis

Cite this

Development of a novel anti-canine CD20 monoclonal antibody with diagnostic and therapeutic potential. / Ito, Daisuke; Brewer, Susan; Modiano, Jaime F.; Beall, Melissa J.

In: Leukemia and Lymphoma, Vol. 56, No. 1, 01.01.2015, p. 219-225.

Research output: Contribution to journalArticle

@article{03b9810ff226418db1009817ee096078,
title = "Development of a novel anti-canine CD20 monoclonal antibody with diagnostic and therapeutic potential",
abstract = "In humans, passive immunotherapy with anti-CD20 monoclonal antibodies (mAbs) has created immeasurable improvements in outcomes of patients with B-cell malignancies. However, the lack of comparable reagents has precluded development of this approach in dogs. We developed a novel anti-canine CD20 mAb designated as 6C8. 6C8 recognized the extracellular domain of canine CD20 and showed high-affinity binding to canine CD20 in solution, as well as in its native conformation on canine B-cells. The 6C8 target was expressed invariably in B-cell lineage cells, but not in T-cells or myeloid cells. 6C8 promoted phagocytosis of B-cell lymphoma cells by macrophages, but in its current framework, it did not induce direct cytotoxicity or complement dependent cytotoxicity. In summary, we have established a novel anti-canine CD20 mAb that is useful as a diagnostic tool to phenotype B-cells, and which could be integrated as a tool for passive immunotherapy to treat dogs with B-cell disorders.",
keywords = "B-cell lymphoma, CD20, Dogs, Monoclonal antibody, Phagocytosis",
author = "Daisuke Ito and Susan Brewer and Modiano, {Jaime F.} and Beall, {Melissa J.}",
year = "2015",
month = "1",
day = "1",
doi = "10.3109/10428194.2014.914193",
language = "English (US)",
volume = "56",
pages = "219--225",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Development of a novel anti-canine CD20 monoclonal antibody with diagnostic and therapeutic potential

AU - Ito, Daisuke

AU - Brewer, Susan

AU - Modiano, Jaime F.

AU - Beall, Melissa J.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - In humans, passive immunotherapy with anti-CD20 monoclonal antibodies (mAbs) has created immeasurable improvements in outcomes of patients with B-cell malignancies. However, the lack of comparable reagents has precluded development of this approach in dogs. We developed a novel anti-canine CD20 mAb designated as 6C8. 6C8 recognized the extracellular domain of canine CD20 and showed high-affinity binding to canine CD20 in solution, as well as in its native conformation on canine B-cells. The 6C8 target was expressed invariably in B-cell lineage cells, but not in T-cells or myeloid cells. 6C8 promoted phagocytosis of B-cell lymphoma cells by macrophages, but in its current framework, it did not induce direct cytotoxicity or complement dependent cytotoxicity. In summary, we have established a novel anti-canine CD20 mAb that is useful as a diagnostic tool to phenotype B-cells, and which could be integrated as a tool for passive immunotherapy to treat dogs with B-cell disorders.

AB - In humans, passive immunotherapy with anti-CD20 monoclonal antibodies (mAbs) has created immeasurable improvements in outcomes of patients with B-cell malignancies. However, the lack of comparable reagents has precluded development of this approach in dogs. We developed a novel anti-canine CD20 mAb designated as 6C8. 6C8 recognized the extracellular domain of canine CD20 and showed high-affinity binding to canine CD20 in solution, as well as in its native conformation on canine B-cells. The 6C8 target was expressed invariably in B-cell lineage cells, but not in T-cells or myeloid cells. 6C8 promoted phagocytosis of B-cell lymphoma cells by macrophages, but in its current framework, it did not induce direct cytotoxicity or complement dependent cytotoxicity. In summary, we have established a novel anti-canine CD20 mAb that is useful as a diagnostic tool to phenotype B-cells, and which could be integrated as a tool for passive immunotherapy to treat dogs with B-cell disorders.

KW - B-cell lymphoma

KW - CD20

KW - Dogs

KW - Monoclonal antibody

KW - Phagocytosis

UR - http://www.scopus.com/inward/record.url?scp=84922350495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922350495&partnerID=8YFLogxK

U2 - 10.3109/10428194.2014.914193

DO - 10.3109/10428194.2014.914193

M3 - Article

VL - 56

SP - 219

EP - 225

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1

ER -